| Primary |
| Breast Cancer |
48.1% |
| Hepatic Neoplasm Malignant |
9.5% |
| Breast Cancer Recurrent |
4.4% |
| Prophylaxis |
4.2% |
| Gastric Cancer |
3.8% |
| Premedication |
3.4% |
| Hypersensitivity |
3.0% |
| Insomnia |
2.2% |
| Plasma Cell Myeloma |
2.2% |
| Vomiting |
2.0% |
| Bladder Cancer Recurrent |
1.8% |
| Breast Cancer Metastatic |
1.8% |
| Metastases To Liver |
1.8% |
| Preoperative Care |
1.8% |
| Benign Prostatic Hyperplasia |
1.6% |
| Cataract |
1.6% |
| Constipation |
1.6% |
| Gastritis Atrophic |
1.6% |
| Hodgkin's Disease |
1.6% |
| Urinary Tract Infection |
1.6% |
|
| Interstitial Lung Disease |
29.2% |
| Pneumocystis Jiroveci Pneumonia |
7.3% |
| Renal Failure Acute |
6.3% |
| White Blood Cell Count Decreased |
6.3% |
| Hyponatraemia |
5.2% |
| Hypothyroidism |
5.2% |
| Hepatitis B |
4.2% |
| Panniculitis |
4.2% |
| Feeling Abnormal |
3.1% |
| Hepatitis |
3.1% |
| Pulmonary Oedema |
3.1% |
| Rectal Ulcer |
3.1% |
| Rhabdomyolysis |
3.1% |
| Toxic Epidermal Necrolysis |
3.1% |
| Tremor |
3.1% |
| Death |
2.1% |
| Febrile Neutropenia |
2.1% |
| Hepatic Function Abnormal |
2.1% |
| Hepatic Necrosis |
2.1% |
| Hypoaesthesia |
2.1% |
|
| Secondary |
| Breast Cancer |
54.2% |
| Metastases To Bone |
6.5% |
| Hepatic Neoplasm Malignant |
5.4% |
| Uterine Cancer |
3.1% |
| Prophylaxis |
3.0% |
| Therapeutic Embolisation |
2.7% |
| Breast Cancer Recurrent |
2.5% |
| Breast Cancer Metastatic |
2.4% |
| Hypertension |
2.1% |
| Hyperlipidaemia |
1.9% |
| Biliary Cirrhosis Primary |
1.8% |
| Gastric Ulcer Haemorrhage |
1.8% |
| Neuropathy Peripheral |
1.8% |
| Pollakiuria |
1.8% |
| Drug Use For Unknown Indication |
1.6% |
| Non-hodgkin's Lymphoma |
1.6% |
| Ovarian Cancer |
1.6% |
| Prophylaxis Of Nausea And Vomiting |
1.6% |
| Gastric Cancer |
1.3% |
| Breast Cancer Stage Ii |
1.2% |
|
| White Blood Cell Count Decreased |
13.3% |
| Pulmonary Oedema |
10.8% |
| Acute Myeloid Leukaemia |
8.3% |
| Febrile Bone Marrow Aplasia |
7.5% |
| Interstitial Lung Disease |
7.5% |
| Neutrophil Count Decreased |
5.8% |
| Vomiting |
5.8% |
| Treatment Related Secondary Malignancy |
5.0% |
| Off Label Use |
4.2% |
| Rhabdomyolysis |
4.2% |
| Ventricular Extrasystoles |
4.2% |
| Hepatitis B |
3.3% |
| Bacterial Sepsis |
2.5% |
| Febrile Neutropenia |
2.5% |
| Hepatic Necrosis |
2.5% |
| Nausea |
2.5% |
| Post Procedural Infection |
2.5% |
| Pyrexia |
2.5% |
| Septic Shock |
2.5% |
| Skin Discolouration |
2.5% |
|
| Concomitant |
| Breast Cancer |
37.7% |
| Metastases To Bone |
19.9% |
| Postoperative Care |
6.6% |
| Prophylaxis Of Nausea And Vomiting |
4.4% |
| Breast Cancer Recurrent |
3.7% |
| Hepatic Neoplasm Malignant |
3.3% |
| Tumour Marker Increased |
3.3% |
| Ovarian Cancer |
2.6% |
| Drug Use For Unknown Indication |
2.1% |
| Chemotherapy |
1.9% |
| Metastases To Lymph Nodes |
1.9% |
| Rheumatoid Arthritis |
1.9% |
| Breast Cancer Metastatic |
1.6% |
| Metastases To Central Nervous System |
1.6% |
| Constipation |
1.4% |
| Drug Toxicity Prophylaxis |
1.4% |
| Product Used For Unknown Indication |
1.4% |
| Cancer Pain |
1.2% |
| Herpes Zoster |
1.2% |
| Bladder Cancer |
0.9% |
|
| Tooth Extraction |
19.0% |
| Injection Site Phlebitis |
11.9% |
| Tumour Marker Increased |
7.1% |
| Osteonecrosis |
6.0% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
6.0% |
| Hepatic Function Abnormal |
4.8% |
| Pyrexia |
4.8% |
| X-ray Dental |
4.8% |
| Acute Myeloid Leukaemia |
3.6% |
| Intestinal Ischaemia |
3.6% |
| Metastatic Neoplasm |
3.6% |
| Palpitations |
3.6% |
| Pruritus |
3.6% |
| Tooth Loss |
3.6% |
| Breast Cancer Female |
2.4% |
| Fall |
2.4% |
| Osteonecrosis Of Jaw |
2.4% |
| Pain In Jaw |
2.4% |
| Polymyositis |
2.4% |
| Renal Failure Acute |
2.4% |
|
